On Mar. 16, 2020, Moderna announced it has released the first batch of mRNA-1273, the Companyﾒs vaccine against the novel coronavirus, for human use. Vials of mRNA-1273 have been shipped to the NIH to be used in the planned Phase 1 study in the U.S.